Daejeon, South Korea

Hidetaka Kaku

This inventor holds 1 USPTO granted patent. Top assignees: Lg Life Sciences, Limited, Yamanouchi Pharmaceutical Company Ltd.. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hidetaka Kaku. Retrieved from https://idiyas.com/inventor/hidetaka-kaku-veyamdfi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 17.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hidetaka Kaku: Innovator in Melanocortin Receptor Agonists

Introduction

Hidetaka Kaku is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmacology, particularly through his work on melanocortin receptor agonists. His innovative approach has led to the development of a compound that holds promise for various therapeutic applications.

Latest Patents

Hidetaka Kaku holds a patent for melanocortin receptor agonists. The patent describes a compound of formula 1, along with its pharmaceutically acceptable salt, hydrate, solvate, or isomer. This compound is effective as an agonist of the melanocortin receptor and is part of an agonistic composition that includes the same as an active ingredient.

Career Highlights

Throughout his career, Hidetaka Kaku has worked with prominent companies in the pharmaceutical industry. He has been associated with LG Life Sciences and Yamanouchi Pharmaceutical Company Limited. His work in these organizations has allowed him to advance his research and contribute to the development of innovative medical solutions.

Collaborations

Hidetaka Kaku has collaborated with notable colleagues, including Koo Lee and Heui-Sul Park. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.

Conclusion

Hidetaka Kaku's contributions to the development of melanocortin receptor agonists highlight his role as an influential inventor in the pharmaceutical industry. His innovative work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…